

# Kari B Wisinski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8873169/publications.pdf>

Version: 2024-02-01

28  
papers

1,099  
citations

586496

16  
h-index

620720

26  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2319  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abbreviated endocrine therapy duration for low estrogen receptor-positive breast cancer: The counter to extended endocrine therapy. <i>Cancer</i> , 2022, , .	2.0	1
2	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K $\beta/\delta$ , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	3.2	11
3	A phase I study of talazoparib (<sc>BMN</sc> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (<sc>NCI9782</sc>). <i>Cancer Medicine</i> , 2022, 11, 3969-3981.	1.3	11
4	Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative-intent chemotherapy: A Wisconsin Oncology Network study. <i>Cancer</i> , 2021, 127, 801-808.	2.0	10
5	Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier. <i>Clinical Breast Cancer</i> , 2021, 21, 120-127.	1.1	2
6	Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer. <i>Endocrinology</i> , 2021, 162, .	1.4	8
7	Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitations. <i>Cancer</i> , 2021, 127, 3033-3034.	2.0	0
8	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. <i>Nature Cancer</i> , 2021, 2, 658-671.	5.7	34
9	Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. <i>Science Translational Medicine</i> , 2021, 13, eabd4811.	5.8	48
10	Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2553-2567.	1.9	35
11	BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity. <i>Nucleic Acids Research</i> , 2021, 49, 12211-12233.	6.5	29
12	<i>BRCA</i> Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations. <i>Radiology</i> , 2019, 291, 554-569.	3.6	39
13	PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. <i>Cancer</i> , 2018, 124, 2498-2506.	2.0	101
14	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6823-6832.	3.2	66
15	Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2659-2667.	3.2	39
16	Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. <i>Clinical Breast Cancer</i> , 2016, 16, 256-261.	1.1	19
17	Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression. <i>Cancer Discovery</i> , 2016, 6, 516-531.	7.7	164
18	Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 48-59.	1.9	25

#	ARTICLE	IF	CITATIONS
19	Role of the androgen receptor in triple-negative breast cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 186-93.	0.3	68
20	Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 958-965.	0.5	11
21	Screening Magnetic Resonance Imaging Recommendations and Outcomes in Patients at High Risk for Breast Cancer. <i>Breast Journal</i> , 2015, 21, 246-253.	0.4	13
22	A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1 $\alpha$ ,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 416-424.	0.5	0
23	Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 1246-59.	0.0	17
24	Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study. <i>Clinical Breast Cancer</i> , 2014, 14, 205-211.	1.1	8
25	CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis. <i>Cancer Cell</i> , 2014, 25, 21-36.	7.7	215
26	Research Resource: Global Identification of Estrogen Receptor $\beta$ Target Genes in Triple Negative Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2013, 27, 1762-1775.	3.7	52
27	Predictors of Willingness to Participate in Window-of-Opportunity Breast Trials. <i>Clinical Medicine and Research</i> , 2013, 11, 107-112.	0.4	11
28	Identification of Estrogen Receptor Dimer Selective Ligands Reveals Growth-Inhibitory Effects on Cells That Co-Express ER $\alpha$ and ER $\beta$ . <i>PLoS ONE</i> , 2012, 7, e30993.	1.1	62